Skip to main content

Table 2 Descriptive summary of serum utomilumab pharmacokinetic parameter values for Cycle 5

From: A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors

Parameter, UnitsMogamulizumab 1 mg/kg + Utomilumab, by Dose Groupa
1.2 mg/kg100 mg5 mg/kg
n212
AUClast, μg·h/mL907, 144027001620, 9270
AUClast,(dn), μg·h/mL/mg/kg756, 12002490323, 1850
Cmax, μg/mL17.5, 20.027.886.6, 129
Cmax,(dn), μg/mL/mg/kg14.6, 16.725.617.3, 25.8
Ctrough, μg/mL1.30b1.162.19, 5.48
Tlast, h335, 33630925.1, 170
Tmax h2.00, 2.036.001.00, 1.15
  1. aIndividual patient value(s) are presented when N < 3
  2. bOnly 1 patient had quantifiable Ctrough concentrations
  3. AUClast Area under the serum concentration–time profile from time zero to the time of the last quantifiable concentration, Cmax Maximum observed serum concentration, Ctrough Predose concentration during multiple dosing, dn Dose normalized, n Number of patients in the treatment group and contributing to the summary statistics, Tlast Time of last measurable concentration, Tmax Time for Cmax